Acipimox
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09055 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 19 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency | KG + DL |
| 2 | hyperlipidemia due to hepatic triglyceride lipase deficiency | KG + DL |
| 3 | idiopathic copper-associated cirrhosis | KG + DL |
| 4 | hepatoportal sclerosis | KG + DL |
| 5 | primitive portal vein thrombosis | KG + DL |
| 6 | early-onset familial noncirrhotic portal hypertension | KG + DL |
| 7 | hepatopulmonary syndrome | KG + DL |
| 8 | hyperlipidemia | KG + DL |
| 9 | cholesterol-ester transfer protein deficiency | KG + DL |
| 10 | hepatic porphyria | KG + DL |
| 11 | fibroma of prostate | KG + DL |
| 12 | hyperalphalipoproteinemia | KG + DL |
| 13 | familial hypercholesterolemia | KG + DL |
| 14 | hypertriglyceridemia, familial | KG + DL |
| 15 | benign reproductive system neoplasm | KG + DL |
| 16 | benign prostate phyllodes tumor | KG + DL |
| 17 | Brenner tumor | KG + DL |
| 18 | prostate cancer/brain cancer susceptibility | KG + DL |
| 19 | familial chylomicronemia syndrome | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.